Movement Alert|Elevance Health Intraday Rise 3.42% in Regular Trading, guidance reaffirmation and higher price target support sentiment

Market Focus11-16 23:05

On November 16, Elevance Health rose 3.42% in Regular Trading, trading at $444.08 per share, with turnover of $58.62 million.

The clearest recent catalyst in the news flow was the company’s reaffirmation of full-year adjusted EPS of at least $29 and benefit expense ratio guidance of 90.2% plus or minus 50 basis points, alongside Cantor Fitzgerald’s price-target increase to $493 from $450.

That backdrop followed stronger third-quarter results reported on October 21, when Elevance Health posted adjusted EPS of $6.99 on revenue of $50.44 billion, both above consensus, and raised its full-year adjusted EPS outlook to at least $29. Recent coverage also noted that while investors remain attentive to Medicaid utilization pressure and expected exits from some state Medicaid markets, the reaffirmed guidance and latest target-price increase reinforced expectations for earnings resilience.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment